Transgene (TNG) Investor presentation summary

Company overview and strategy

• Clinical-stage biotech focused on individualized neoantigen therapeutic vaccines (INTVs) for early-stage solid tumors, leveraging viral vector-based immunotherapies and strong IP portfolio.

• Lead platform myvac® has matured into a multi-asset, AI-powered platform with two clinical-stage candidates (TG4050 and TG4070) and a novel MVA-based prophylactic vaccine (TG-MVA) for mpox/smallpox.

• Funded until early 2028, with scalable, automatable manufacturing processes and a leadership team with deep industry experience.

Clinical pipeline and data highlights

• TG4050 (HNSCC): Phase 1 showed 100% 2-year disease-free survival (DFS) in treated patients, robust and durable neoantigen-specific CD8 T cell responses, and a favorable safety profile; Phase 2 ongoing with efficacy data expected by Q1 2028.

• TG4070 (NSCLC): Randomized Phase 1 approved, targeting high-risk patients post-surgery who did not achieve major pathological response after neoadjuvant chemo-immunotherapy; combination with nivolumab aims to prevent relapse.

• TG-MVA: Preclinical data show strong protection, immunogenicity, and safety against mpox, with scalable cell-line manufacturing and potential for rapid deployment in public health emergencies.

Scientific and technological innovation

• Proprietary AI tools (VacDesignR®, SNIPER) optimize neoantigen selection and vaccine design, enabling personalized immunotherapy with broad applicability across tumor types.

• Manufacturing platform transitioned from egg-based to cell-line processes, improving scalability, automation, and turnaround time for individualized vaccines.

• Mechanistic studies confirm induction, persistence, and diversification of neoantigen-specific T cell responses, supporting the platform's mode of action.